209 related articles for article (PubMed ID: 19464324)
1. Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Auclair AL; Kleven MS; Barret-Grévoz C; Barreto M; Newman-Tancredi A; Depoortère R
Behav Brain Res; 2009 Nov; 203(2):288-95. PubMed ID: 19464324
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Bruins Slot LA; Kleven MS; Newman-Tancredi A
Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
[TBL] [Abstract][Full Text] [Related]
8. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
9. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
[TBL] [Abstract][Full Text] [Related]
10. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
11. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
12. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
14. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Matsui-Sakata A; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
[TBL] [Abstract][Full Text] [Related]
16. Involvement of presynaptic 5-HT
Mombereau C; Arnt J; Mørk A
Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
18. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Finkel S; Kozma C; Long S; Greenspan A; Mahmoud R; Baser O; Engelhart L
Int Psychogeriatr; 2005 Dec; 17(4):617-29. PubMed ID: 16202186
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of the atypical antipsychotics.
Wooten J
South Med J; 2007 Aug; 100(8):771-2. PubMed ID: 17713300
[No Abstract] [Full Text] [Related]
20. Comparing the side effect profile of the atypical antipsychotics.
Alao AO; Malhotra K; Dewan MJ
West Afr J Med; 2002; 21(4):313-5. PubMed ID: 12665274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
